Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gastroenterol Clin North Am. 2013 Jun;42(2):359-69. doi: 10.1016/j.gtc.2013.01.011. Epub 2013 Mar 1.
Gastric cancer (GC) is a major health burden throughout the world, especially in certain endemic regions. GC is commonly diagnosed at an advanced stage because of the lack of early detection strategies and is usually associated with a dismal outcome. For patients with localized GC (LGC), surgery is the best cure: cure rates are highly associated with the surgical pathology stage. Adjunctive therapies improve the cure rates by about an additional 10%. Therefore, a multimodality approach is highly recommended for all patients with LGC. This article highlights some of the therapeutic advances made against GC and features important ongoing trials.
胃癌（GC）是全球范围内的主要健康负担，尤其是在某些高发地区。由于缺乏早期检测策略，GC 通常在晚期才被诊断出来，且通常预后较差。对于局限性胃癌（LGC）患者，手术是最佳治疗方法：治愈率与手术病理分期高度相关。辅助治疗可使治愈率提高约 10%。因此，强烈建议所有 LGC 患者采用多模式治疗。本文重点介绍了针对 GC 取得的一些治疗进展，并介绍了正在进行的重要试验。
